Malignant pleural mesothelioma: an update on biomarkers and treatment.
about
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusionMesothelioma - Update on Diagnostic StrategiesIdentification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinomaCD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk AnalysisNovel systemic therapy against malignant pleural mesothelioma.An in vivo platform for tumor biomarker assessment.Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesotheliomaMalignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review.The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesotheliomaSequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.Unusual presentation and location pleural malignant mesothelioma.Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic targetPARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell.The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma.Soluble markers for diagnosis of malignant pleural mesothelioma.Medical treatment of mesothelioma: anything new?Metastases to the oral region from pleural mesothelioma: Clinicopathologic review.Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.Asbestos-related pleuropulmonary diseases: benign and malignant.Therapies currently in Phase II trials for malignant pleural mesothelioma.Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells.Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspasesSynthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.Patterns of care and survival among patients with malignant mesothelioma in the United States.Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.Clinical and biologic prognostic factors in malignant pleural mesothelioma.
P2860
Q27853125-7F069FBE-4C94-48D9-9744-3D3F9E9EDF3AQ28387980-876ECC04-7E69-4C19-B7F7-7DDE41051A65Q28392693-43EF0A0A-CE57-4AAE-9E4F-BCF0B172FACBQ28634010-FF57165F-CB5D-4514-992B-2C362A4C9B6CQ33556551-63642B53-F5DE-45D5-9EC3-7A91B8306050Q33819781-4FE805E9-D1E7-49DF-8226-BD9FEC8276EFQ33890499-4FFAF847-BDEB-43DD-8B0D-E34C29AC47D3Q34064633-3265AF73-3147-417C-8E06-0D1C9555F558Q34271064-D032C5FA-FA22-452F-8E24-D072E5BFE6B5Q34425631-EB12CF7D-B61B-4CDD-B72D-47F770BC56F6Q35686558-14C28EF6-D6B3-4832-80BB-E562A1E646A2Q35832320-B7519BD3-04EC-44E3-9F97-7DFF5C9F6272Q35834928-B697DD2C-DCAD-4CEF-B53C-60622BB419B3Q35904195-AF91C55D-6C9B-4F1D-962E-659F1708314BQ36244087-1A20C101-98A1-4C6C-BA2C-2772684BA7F7Q36815218-70A6F676-6EF9-4795-96FF-533DAB3B0F71Q36986796-DCAAF605-C6AE-41D1-AC50-5D98E0E72E30Q37207654-5F55F7A4-2390-4A7E-AC84-B142975C8799Q37293979-F3ECFA23-570A-4722-A7BB-38240F0C802CQ37381458-7B02F249-F823-4EB0-8209-7BC57C065742Q37585990-0750E3D6-91A9-4DBF-939E-CAB4E8823A31Q37813173-5C9B066E-D28D-4FF2-8A2C-6A2713C5C4B0Q37862752-B4B6F907-555E-4FC8-A727-FB8F3BC80B0FQ37866663-1CED84C4-54A6-4858-97A5-AFF274A466FDQ37956213-23A217F5-3A96-486B-B6EB-8BC6B6B2B5FCQ37975136-352C7A64-3F78-4642-A1F7-3CB7A8A8309BQ38018217-21E3D02C-69CE-4554-8CD5-5CA03E07D73FQ38118385-6AD692BF-97BB-4BAE-B539-2A2AA2E7CF98Q38764836-7AB0B466-099A-4234-9BFB-DD9DA8CD72DAQ38927008-4353E5E1-64E8-4252-9E7D-577A1C72A902Q39093077-8DCCA86C-C448-41C4-B1CF-93E56F98141AQ39228453-FDDCDA07-E0DF-43D5-9C41-8D8D47FAC82DQ39404847-726E53A4-E1DA-44E1-9133-FAA5153CB611Q41593380-F80D04A4-AE34-4008-AD27-78E554EDAD21Q41856729-34504E16-71C7-4FBF-AB50-858279C26860Q41920935-2E5F3F92-7016-4244-B9A2-B138876798E1Q46122543-654CC30F-F41F-40DA-BF17-176B6D9B0194Q49389798-9CDD1437-C3D1-4439-A23A-4A6C38FF2E7AQ49804857-26F87D9F-5EF3-4CEA-BA65-57CD78D807CEQ50050310-476B96D4-AA1E-4952-B3AE-D5C161A9DCBB
P2860
Malignant pleural mesothelioma: an update on biomarkers and treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Malignant pleural mesothelioma: an update on biomarkers and treatment.
@en
Malignant pleural mesothelioma: an update on biomarkers and treatment.
@nl
type
label
Malignant pleural mesothelioma: an update on biomarkers and treatment.
@en
Malignant pleural mesothelioma: an update on biomarkers and treatment.
@nl
prefLabel
Malignant pleural mesothelioma: an update on biomarkers and treatment.
@en
Malignant pleural mesothelioma: an update on biomarkers and treatment.
@nl
P356
P1433
P1476
Malignant pleural mesothelioma: an update on biomarkers and treatment.
@en
P2093
Hedy Lee Kindler
Mandira Ray
P304
P356
10.1378/CHEST.08-2665
P407
P577
2009-09-01T00:00:00Z